TABLE 2.

Persistence of Oral and Cervical HPV Alpha Mucosal Types Among the Women With Detectable Oral HPV DNA at the 4-y Visit, Stratified by Vaccine Arm

	Overall (n = 350)		HPV Vaccine Arm (n = 162)		Control Arm (n = 188)*
Test Result	No. HPVs Detected at the 4-y Visit	% (95% CI) Persisted (Detected Again at the 6-y Visit)	No. HPVs Detected at the 4-y Visit	% (95% CI) Persisted (Detected Again at 6-y Visit)	No. HPVs Detected at the 4-y Visit	(% 95% CI) Persisted (Detected Again at 6-y Visit)
Any oral HPV	82	17.6% (10.9–28.5%)	27	23.6% (11.7–47.5%)	55	14.8% (7.8–28.2%)
Carcinogenic oral HPV	47	15.4% (7.9–30.1%)	11	27.7% (10.8–70.9%)	36	11.3% (4.6–28.1%)
Noncarcinogenic oral HPV	35	20.5% (10.8–39.0%)	16	19.6% (7.2–53.2%)	19	21.3% (9.2–49.3%)
Uncharacterized oral HPV	156	n/a	79	n/a	77	n/a
Any cervical HPV†	223	17.7% (13.1–23.9%)	84	19.3% (13.3–27.9%)	139	16.5% (10.8–25.2%)
Carcinogenic cervical HPV†	131	19.7% (13.6–28.6%)	42	20.5% (11.4–37.2%)	89	18.4% (11.3–29.9%)
Noncarcinogenic cervical HPV†	92	14.9% (9.1–24.6%)	42	17.9% (10.4–30.7%)	50	13.4% (6.6–27.4%)
Uncharacterized cervical HPV†	22	n/a	12	n/a	10	n/a

^*The majority of the women from the control arm were also HPV16/18 vaccinated after the 4 year visit.

^†Excludes 1 of the 350 woman who did not have cervical testing at the 4-year visit.

n/a indicates not applicable.